Want to see KROS full AI Analyst Report?
KROS Stock Chart & Stats
$10.06
$0.28(2.78%)
At close: 4:00 PM EDT
$10.06
$0.28(2.78%)
Day’s Range― - ―
52-Week Range$9.69 - $22.55
Previous CloseN/A
Volume34.91K
Average Volume (3M)282.35K
Market Cap
$202.27M
Enterprise Value-$48.47
Total Cash (Recent Filing)$281.50M
Total Debt (Recent Filing)$16.31M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 12, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding19,791,838
10 Day Avg. Volume184,860
30 Day Avg. Volume282,353
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.00Price Target Upside88.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.82
Revenue Forecast (FY)$3.42M
Bulls Say, Bears Say
Bulls Say
Takeda Collaboration And Milestone FrameworkA material global license with Takeda creates durable, non-dilutive financing optionality and upside via milestone and royalty streams. Structural partner economics and upfront funding reduce sole reliance on equity raises and align incentives for late-stage development and commercialization timelines.
Phase 3 ELRiSE Initiation For ElriterceptAdvancing elritercept into a randomized Phase 3 is a durable clinical de-risking event: it validates the program, creates clear regulatory/clinical readthroughs, and materially increases the probability of future milestone/royalty realizations and potential commercialization over a multi-quarter horizon.
Conservative Balance Sheet With Low LeverageLow leverage provides financial flexibility to fund R&D or absorb operational volatility without immediate refinancing pressure. A conservative capital structure supports multi-quarter runway, strategic option-taking, and bargaining power in collaborations or licensing negotiations.
Bears Say
Highly Volatile Revenue And EarningsLarge swings in reported revenue and profitability reflect reliance on lumpy, milestone-driven receipts rather than recurring product sales. This volatility undermines forecasting, budgeting, and valuation stability, complicating multi-quarter planning for operations and investment in core programs.
Deteriorated Operating And Free Cash FlowMaterial negative OCF and FCF in the trailing period signal renewed cash burn and potential need for external funding if milestone timing lags. Persistent negative cash generation reduces runway and may force dilution or constrain R&D prioritization over the next several quarters.
Business Model Dependent On Irregular Milestone/collaboration PaymentsReliance on infrequent collaboration payments creates lumpy, unpredictable revenue streams and cashflow. Without commercial products, the company is exposed to timing risk of partner-triggered payments and must manage operations around event-driven income rather than stable sales.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics, Inc.’s price range in the past 12 months?
Keros Therapeutics, Inc. lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics, Inc.’s market cap?
Keros Therapeutics, Inc.’s market cap is $202.27M.
When is Keros Therapeutics, Inc.’s upcoming earnings report date?
Keros Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Keros Therapeutics, Inc.’s earnings last quarter?
Keros Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.023 by -$0.187.
Is Keros Therapeutics, Inc. overvalued?
According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued.
Does Keros Therapeutics, Inc. pay dividends?
Keros Therapeutics, Inc. does not currently pay dividends.
What is Keros Therapeutics, Inc.’s EPS estimate?
Keros Therapeutics, Inc.’s EPS estimate is -1.34.
How many shares outstanding does Keros Therapeutics, Inc. have?
Keros Therapeutics, Inc. has 19,791,838 shares outstanding.
What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?
Keros Therapeutics, Inc. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.023. Following the earnings report the stock price went down -8.34%.
Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (88.87% Upside)
$19.00 (88.87% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.20%
Trailing 12-Months
Company Description
Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$19.00
▲(88.87% Upside)
Technical Analysis
Gyre Therapeutics
―
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
5.01% Insiders
19.58% Mutual Funds
0.02% Other Institutional Investors
60.32% Public Companies and
Individual Investors